ACS Chemical Neuroscience Molecule Spotlight on RG1678

作者：Hopkins Corey R^*

来源：ACS Chemical Neuroscience, 2011, 2(12): 685-686.

DOI：10.1021/cn200108z

• Schizophrenia
• negative symptoms
• RG1678
• glycine transporter-1 inhibitor
• GlyT1

RG1678 is a glycine transporter-1 inhibitor currently in Phase III trials for the treatment of the negative symptoms of schizophrenia and is being developed by Roche (in combination with Chugai). Recent Phase II data shows that RG1678 is effective in reducing the negative symptoms when given in combination with second generation antipsychotics.

• 出版日期2011-12